Factor V Bethesda Units, Plasma
Use
This test is useful for detecting and quantifying the presence and titer of a specific factor inhibitor directed against coagulation factor V. Significant bleeding can result from the presence of a coagulation factor inhibitor, which could be life-threatening. It complicates the treatment process of a decreased factor level due to hemophilia or its acquired nature. The titer of the inhibitor may determine the mode of treatment. Bethesda units provide a standardization to give a uniform definition of an inhibitor.
Special Instructions
Not provided.
Limitations
The test performance and characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration. Cautionary conditions were not significant, indicating minimal risk of diagnostic confusion under normal specimen handling.
New York Approved
Methodology
Other
Biomarkers
LOINC Codes
- 3191-4 - Fact V Inhib PPP-aCnc
- 3191-4 - Fact V Inhib PPP-aCnc
Result Turnaround Time
2-5 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
Not provided
Minimum Volume
Not provided
Container
N/A
Causes for Rejection
Gross hemolysis, lipemia, or icterus
Stability Requirements
| Temperature | Period |
|---|---|
| Frozen | 14 days |